

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (currently amended) An isolated RNase A superfamily polypeptide having an N-terminus of the sequence: X¹X²SLX³V (SEQ ID NO:9), wherein X¹ represents methionine ~~or is absent~~, X² represents glycine or is absent, and X³ represents ~~an~~ any amino acid residue (~~SEQ ID NO:9~~), said RNase A superfamily polypeptide being selectively toxic to a proliferating endothelial cell.
2. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 having SEQ ID NO:2.
3. (canceled)
4. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 having SEQ ID NO:4.
5. (canceled)
6. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the N-terminus is MSLHV (SEQ ID NO:11).
7. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the N-terminus is MGSLHV (SEQ ID NO:10).
8. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the N-terminus is attached to the eosinophil derived neurotoxin (EDN) protein.
9. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the proliferating endothelial cell is a neoplastic endothelial cell.

10. (currently amended) An isolated RNase A superfamily polypeptide of claim 1 wherein the proliferating endothelial cell is a non-neoplastic endothelial cell.

11. (currently amended) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is a Kaposi sarcoma KS Y-1 cell.

12. (currently amended) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is a KS Y-3 cell.

13. (currently amended) An isolated RNase A superfamily polypeptide of claim 9 wherein the neoplastic endothelial cell is selected from the group consisting of KS 1, KS 2, KS 3, KS 4, KS 5, and KS 6 cells.

14. (currently amended) A pharmaceutical composition comprising

- a. a unit dosage RNase A superfamily polypeptide comprising an N-terminus of the sequence: $X^1X^2SLX^3V$ (SEQ ID NO:9), wherein X^1 represents methionine ~~or is absent~~, X^2 represents glycine or is absent, and X^3 represents ~~an~~ any amino acid residue (~~SEQ ID NO:9~~), said RNase A superfamily polypeptide being selectively toxic to a proliferating endothelial cell; and
- b. a pharmaceutically acceptable carrier.

15-21. (canceled)